Immatics Biotechnologies' Series E Round

Immatics Biotechnologies raised a round of funding on October 04, 2017.

immatics biotechnologies is a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer. immatics' lead product, IMA901, is in a pivot…

Articles about Immatics Biotechnologies' Series E Round: